EffectS of CAnnabidiol in Patients: Evaluation

NCT04405414 | Completed

• 1 other identifier: RC19_0405
• Study Type: observational
• Target: 746
• Locations: 1 country
• Sites: 1

Brief Summary

Since its recent marketizing in France, the cannabidiol (CBD), a major component of cannabis, is used in many over-the-counter products in France. Some painful patients or patients suffering from addiction seem to use the CBD in search of therapeutic effects. Yet, there are no data available for patients in algology and addictology, particularly with regard to the prevalence of the use of CBD, the effects sought and felt. Faced with the emergence of the use of a substance with a therapeutic purpose but outside a medical framework and without monitoring of adverse effects, it becomes essential to characterize the use of CBD. The main objective of the study is therefore to assess the prevalence of CBD users in algology and addictology departments. Secondary objectives are to characterize the use of CBD as well as the users of CBD, and to evaluate the impact of the use of CBD on other psychoactive substances use or current drug treatments and the drug liking of CBD.

Conditions

Substance-Related Disorders

Keywords

Cannabidiol; prevalence; epidemiology; pain; substance-related disorders

Outcome Measures

Primary Outcomes (1)

• Prevalence of CBD users

  For all patients included in the study, the use of CBD during the last 12 months (yes or no) will be collected.

  through study completion, an average of 2 year

Secondary Outcomes (4)

• Characterization of the use of CBD

  through study completion, an average of 2 year

• Characterization of CBD users

  through study completion, an average of 2 year

• Impact of the use of CBD

  through study completion, an average of 2 year

• CBD drug-liking

  through study completion, an average of 2 year

Interventions

Form OTHER

Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Physicians from algology and addictology departments will propose the study to all patients who meet the inclusion criteria during a medical consultation (in hospitalization or ambulatory care)

You may qualify if:

• Minimum age of 18 years
• Giving oral non opposition to participate.

You may not qualify if:

• Adults under guardianship or curator
• Patients unable to respond to the research evaluation (cerebral function disorder, difficulty to understand, read or write French language).

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (1)

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

Location

MeSH Terms

Conditions

Substance-Related Disorders; Pain

Interventions

Metabolism

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders; Mental Disorders; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2020
• First Posted: May 28, 2020
• Study Start: May 6, 2020
• Primary Completion: July 26, 2021
• Study Completion: July 26, 2021
• Last Updated: September 22, 2021

Record last verified: 2021-09

Locations

FR (1)